Want to see GNLX full AI Analyst Report?
GNLX Stock Chart & Stats
$2.72
$0.03(1.21%)
At close: 4:00 PM EDT
$2.72
$0.03(1.21%)
Day’s Range― - ―
52-Week Range$2.29 - $8.54
Previous CloseN/A
Volume44.18K
Average Volume (3M)349.99K
Market Cap
$114.92M
Enterprise Value$119.08
Total Cash (Recent Filing)$18.67M
Total Debt (Recent Filing)$2.42M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding45,245,335
10 Day Avg. Volume269,246
30 Day Avg. Volume349,993
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.67Price Target Upside623.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageRelatively low leverage gives Genelux more financial flexibility than a heavily indebted biotech and limits interest-related pressure. This provides some balance-sheet support while the company funds clinical development, although continued losses could still increase financing needs.
Oncolytic Immunotherapy PlatformA proprietary virus-based immunotherapy platform could support development across multiple cancer indications and combination approaches. If clinical data are successful, the platform may create several opportunities from shared scientific and development capabilities rather than relying on one narrow program.
Multiple Clinical Development OpportunitiesClinical evaluation across ovarian cancer and other indications broadens the potential addressable opportunity and creates multiple paths for development. This diversification may improve the strategic value of the pipeline if one indication or combination produces compelling clinical evidence.
Bears Say
Near-Zero Revenue And Large LossesGenelux has no established commercial revenue base to offset research and development costs, leaving financial performance dependent on future clinical and regulatory success. The scale of current losses indicates that meaningful operating profitability is unlikely without a successful product or partnership.
Heavy Cash BurnSustained negative operating and free cash flow means the business is not self-funding its clinical programs. Continued trials will likely require substantial external capital, creating financing, dilution, and execution risks that can persist until a product or collaboration generates cash.
Weak Revenue Trajectory And Gross ProfitThe sharp decline in revenue and recurring negative gross profit provide little evidence of commercial traction or near-term operating leverage. This weak base increases dependence on clinical milestones and financing, while making it harder to absorb the fixed costs of biotech development.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $2.29 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $114.92M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Nov 18, 2026 which is in 62 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 13, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.013.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 45,245,335 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went up 4.183%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (623.04% Upside)
$19.67 (623.04% Upside)
Blogger Sentiment
Bullish
GNLX Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $193.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genelux Corp.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$19.67
▲(623.04% Upside)
Technical Analysis
Ownership Overview
7.02% Insiders
4.62% Mutual Funds
10.87% Other Institutional Investors
73.51% Public Companies and
Individual Investors